The Food and Drug Administration recently approved India-based Glenmark Pharmaceutical's lidocaine ointment.
The medication reduces itching and pain associated with skin conditions like scrapes, minor burns, bug bites and eczema.
Lidocaine is a generic version of Britain-based AstraZeneca's Xylocaine ointment. Xylocaine reported annual sales of about $373 million for the 12-month period ending in July, according to data from IMS Health.
Glenmark's U.S. portfolio includes 109 products. The company has 62 drug applications pending approval from the FDA.
More articles on supply chain:
5 myths about the EpiPen controversy
4 quotes from supply chain leaders on improving physician engagement
5 ways Mylan continues to dominate the epinephrine market